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Abstract
Introduction: Acute kidney injury (AKI) morbidity 
and mortality rates remain high. Variable AKI outcomes 
have been reported in association with aminophylline 
treatment. This study evaluated AKI outcome in a group 
of Nigerian children treated with aminophylline. 
Methods: This is a retrospective study of AKI in children 
treated with (N=9) and without (N=8) aminophylline. 
Studied outcome indices comprised urine flow rate 
(UFR), duration of oliguria/anuria, progression through 
AKI stages, number of patients requiring dialysis and 
mortality.
Results: Mean ages for the control and aminophylline 
arms were 4.6±2.7 and 4.9±2.1 years (P=0.7), respectively. 
All patients progressed to stage-3 AKI. Baseline median 
UFRs in the aminophylline and control arms were similar 
(0.13 Vs 0.04 ml/kg/hour respectively, P=0.5). The 
median UFR was significantly higher on day-5 (0.8 Vs 
0.1; P=0.03), day-6 (1.0 Vs 0.2; P=0.02), and day-7 (1.2 
Vs 0.2; P=0.03) in the aminophylline than the control 
arm, respectively. Short duration of oliguria/anuria (≤ 6 
days) was more frequently observed in aminophylline-
treated patients compared to controls (77.8% Vs 25.0%; 
odds ratio 0.09; 95% CI: 0.01-0.89; P=0.04). Only the 
aminophylline group maintained steady serum creatinine 
levels. Four out of five patients in the control group were 
dialyzed compared to only one out of eight patients in the 
aminophylline group (odds ratio 0.16; 95% CI: 0.04-0.71; 
P=0.03). Mortality rates were similar in aminophylline-
treated and control patients (33%Vs 25%; hazard ratio 
0.8; 95% CI: 0.1-5.5; P=0.8).
Conclusion: Aminophylline therapy was beneficial 
for patients with AKI in terms of improved UFR and 
reduced need for dialysis, but failed to impact positively 
on survival. 
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Introduction
Acute kidney injury (AKI) is a sudden perturbation of 
kidney function that is frequently associated with high 
morbidity and mortality rates [1-3]. A diagnostic time 
limit of 48 hours was recently introduced to ensure early 
diagnosis, management and prevention of progression to 
irreversible renal function loss [4]. Furthermore, early 
AKI biomarkers that can ensure prompt diagnosis have 
been identified. When these biomarkers become widely 
available to clinical practice,  informed therapeutic 
interventions capable of aborting disease progression, 
morbidity and mortality multiplication can be applied [5,6]. 
In the injured kidney, adenosine is released endogenously 
from the macula densa causing vasoconstriction of the 
renal afferent arterioles via the adenosine A1receptor as 
well as vasodilatation of the renal efferent arterioles via 
the adenosine A2 receptor; thereby reducing the renal 
blood flow and glomerular perfusion pressure leading to 
ischemic kidney injury [7]. One measure that has been 
tried with the objective of achieving better AKI outcome 
is the use of aminophylline (an ethylenediamine coupled 
theophylline) [7-11]. Aminophylline is converted to 
theophylline in the human body, which in turn vasodilates 
the renal afferent arterioles through competitive inhibition 
of adenosine on the adenosine A1 receptor. Thereby, 
aminophylline improves renal blood flow and glomerular 
perfusion pressure and filtration [7, 8]. Because studies 
involving children are few [9-11, 13, 14], little is known 
about the efficacy and outcome of aminophylline therapy 
in childhood AKI. Children with AKI managed in our 
unit between January 2004 and December 2009 received 
different drug treatments aimed at improving outcome; 
one of such drugs was aminophylline. In this study we 
compared the outcome of aminophylline treated children 
to those who did not receive aminophylline treatment. 
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were oliguric in the control arm while there were four 
and five anuric and oliguric patients in the aminophylline 
arm, respectively (P=1.0). While the UFRs for days 5, 
6, and 7 increased significantly from the baseline in the 
aminophylline arm, this was not the case in the control 
group (Figure-1). Similarly, the UFRs for days 5, 6, 
and 7 were significantly higher in the aminophylline 
arm compared to controls (Figure-2). Seven out of 
nine aminophylline-treated patients had short duration 
of oliguria/anuria compared to two out of eight control 
patients (77.8% Vs 25.0%; odds ratio 0.09; 95% CI: 
0.0-0.89; P=0.04). The median baseline and peak Scr for 
the control group were 4.9 (1.5-11.6) and 7.4 (5.6-15.4) 
mg/dl respectively (P=0.01). Similar measurements 
for the aminophylline arm were 2.0 (1.5-5.3) and 8.2 
(6.0-11.0) mg/dl, respectively (P=0.01). Times to peak 
Scr in both the control and aminophylline arms were 
6-12 days (median 8.0) and 4-12 days (median 8.0) 
respectively (P=0.6). The aminophylline arm maintained 
a relatively constant Scr level compared to controls that 
showed progressive and statistically significant increases 
in Scr level (Figure-3). Five out of eight control patients 
required dialysis while eight out of nine patients in 
the aminophylline arm required dialysis (P=0.08) at 
baseline. Four out of five patients who required dialysis 
in the control arm were dialyzed owing to clinical and 
laboratory deterioration. Only one out of eight patients 
in the aminophylline arm who required dialysis was 
dialyzed. Stable clinical and laboratory status as well as 
early diuresis onset following aminophylline treatment 
precluded dialysis in the remaining seven patients (odds 
ratio 0.16; 95% CI: 0.04-0.71; P=0.03). Two out of eight 
patients among the controls died while three out of nine 
patients in the aminophylline arm died (hazard ratio 0.77; 
95% CI: 0.11-5.45; P=0.8). All patients were followed-
up for 7-42 days (median 19 days).
Discussion
Emerging data on aminophylline treatment of AKI 
showed that the agent could be useful in improving 
outcome as demonstrated by improved urine flow rates 
[9-11, 13-15], steady state Scr [11, 15] and reversal of 
nephrotoxic oliguria [10]. In this study, aminophylline 
was significantly associated with improved outcome 
with regards to UFR, oliguria/anuria duration, number of 
patients dialyzed, and Scr level. This occurred despite both 
groups having similar age, gender, etiology and severity 
of kidney injury. Both groups had similar baseline Scr, 
time to peak Scr and prevalence of oliguria/anuria and all 
patients progressed to stage 3 AKI. The increase in UFRs 
from baselines for days 5, 6, and 7, was significantly 
higher for the aminophylline arm compared to controls. 
This is similar to findings in two other controlled studies 
in children [10, 11]. This study also showed aminophylline 
to be protective against prolonged oliguria/anuria. The 
relatively steady Scr levels found in the aminophylline 
arm suggest increased creatinine excretion following 
improved urine flow rates. This effect probably explains 
why patients treated with aminophylline were less likely 
to be dialyzed compared to controls. However, these 
positive impacts of aminophylline on the hemodynamic 
Methods
This retrospective case control study was conducted by 
reviewing the clinical charts of all AKI patients treated 
with or without aminophylline during the period between 
January 2004 and December 2009. Investigated outcome 
indices comprised urine flow rate (UFR), duration 
of oliguria/anuria, progression through AKI stages, 
need for dialysis and mortality. Inclusion criteria were 
AKI diagnosed within 48 hours of onset. Patients were 
included in the aminophylline group if they started a 
72 hour aminophylline infusion within 72 hours of AKI 
onset. Exclusion criteria comprised non-oliguric AKI, 
insufficient serum creatinine (Scr) data, lack of daily 
urine volume records for at least one week, obstructive 
uropathy, bilateral congenital kidney anomaly or other 
forms of chronic kidney disease as well as administration 
of diuretics and/or calcium channel blockers. None 
of our patients received other drugs that can modify 
renal hemodynamics, such as dobutamine, dopamine 
and adrenaline. The clinical records revealed that the 
aminophylline arm received 5 mg/kg/24h (or 0.21 mg/
kg/h) of the medication for 72 hours, usually 6 to 9 hours 
after oliguria/anuria onset. Serum theophylline level 
was not determined. No adverse effect of aminophylline 
was recorded for any of the patients. Aminophylline 
was delivered in 10% dextrose water infusion. The 
AKI network (AKIN) committee diagnostic and staging 
criteria were used [4]. Where baseline Scr was unknown, 
it was determined using the modification of diet in renal 
disease formula {estimated glomerular filtration rate 
(eGFR) =186 x [Scr] – 1.154 x Age – 0.203 x 0.742 (if female) 
x 1.210 (if black)} [12] by assuming a normal pre-morbid 
eGFR value of 100 ml/min/1.73m2 in the patient as 
recommended by AKIN [4]. Pre-treatment and daily 
biochemical evaluations including Scr were performed 
in all patients. AKI was staged both at baseline and at 
the peak of kidney injury (highest recorded Scr before 
normalization or death) using the AKIN-Scr criterion. 
The baseline UFR was determined from at least a 6-hour 
urine output. UFR in the aminophylline and control arms 
for days 5, 6, and 7 were compared. Diuresis onset was 
regarded as early if UFR ≥ 0.5 ml/kg/h occurred within 
6 days and late if it occurred after 6 days of  AKI onset. 
The study was conducted at the Pediatric Nephrology and 
Hypertension Unit of the Obafemi Awolowo University 
Teaching Hospitals Complex, Osun State, Nigeria. 
The study conformed to the provisions of the revised 
Declaration of Helsinki, Edinburg, 2000. Our institutional 
ethics and research committee approved the study.
Data analyses were performed using the SPSS version 
15.0 for Windows (2006 SPSS Inc.). Descriptive 
statistics comprised median, mean, standard deviation, 
percentages, and proportions. The comparative statistics 
used were Chi-square test, Fisher’s exact test, Student’s 
t-test, Wilcoxon signed ranks test for comparison of the 
medians and odds or hazard ratio where appropriate. 
Kaplan-Meier survival analysis and the log rank test 
were used to compare survival. A P value < 0.05 was 
considered statistically significant.
Results
Sixteen AKI cases were treated with aminophylline 
overall. Seven of the 16 patients were excluded because 
they had received in addition to aminophylline either 
furosemide or a calcium channel blocker or both. 
Overall, 17 patients satisfied the inclusion criteria with 
nine and eight patients in the aminophylline and control 
arms, respectively. The mean ages for the control and 
aminophylline arms were 4.6 ± 2.7 (1.5-10.0) and 4.9 ±2.1 
(2.2-8.5) years, respectively (P=0.7). The aminophylline 
arm contained seven males and two females while the 
control arm contained four males and four females 
(P=0.2). Patients in the aminophylline arm received 
50-125 (81 ± 25) mg of aminophylline per day. Etiologies 
of AKI in both groups of patients are summarized in 
Table-1. All patients progressed to the most severe form 
of AKI (stage 3). Four patients were anuric and four 
Table 1: Etiology of acute kidney injury in the aminophylline and control arms
Acute kidney injury etiology Aminophylline arm (N=9)
Control 
arm (N=8)
P. falciparum malaria associated hemoglobinuria 5 3
Glucose 6-phosphate dehydrogenase enzyme deficiency associated hemoglobinuria 1 3
Septicemia 2 0
Gastroenteritis associated severe dehydration 0 1
Acute glomerulonephritis 0 1
Lupus nephritis 1 0
Figure 1: Box plots comparing the median increase in urine flow rates from baseline to days 5, 6 and 7 in the aminophylline 
and control arms
The lower and the upper arm of each box plot represent the 5th and 95th percentiles while the bottom and top of each box represents the 25th and 75th 
percentiles respectively.
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were oliguric in the control arm while there were four 
and five anuric and oliguric patients in the aminophylline 
arm, respectively (P=1.0). While the UFRs for days 5, 
6, and 7 increased significantly from the baseline in the 
aminophylline arm, this was not the case in the control 
group (Figure-1). Similarly, the UFRs for days 5, 6, 
and 7 were significantly higher in the aminophylline 
arm compared to controls (Figure-2). Seven out of 
nine aminophylline-treated patients had short duration 
of oliguria/anuria compared to two out of eight control 
patients (77.8% Vs 25.0%; odds ratio 0.09; 95% CI: 
0.0-0.89; P=0.04). The median baseline and peak Scr for 
the control group were 4.9 (1.5-11.6) and 7.4 (5.6-15.4) 
mg/dl respectively (P=0.01). Similar measurements 
for the aminophylline arm were 2.0 (1.5-5.3) and 8.2 
(6.0-11.0) mg/dl, respectively (P=0.01). Times to peak 
Scr in both the control and aminophylline arms were 
6-12 days (median 8.0) and 4-12 days (median 8.0) 
respectively (P=0.6). The aminophylline arm maintained 
a relatively constant Scr level compared to controls that 
showed progressive and statistically significant increases 
in Scr level (Figure-3). Five out of eight control patients 
required dialysis while eight out of nine patients in 
the aminophylline arm required dialysis (P=0.08) at 
baseline. Four out of five patients who required dialysis 
in the control arm were dialyzed owing to clinical and 
laboratory deterioration. Only one out of eight patients 
in the aminophylline arm who required dialysis was 
dialyzed. Stable clinical and laboratory status as well as 
early diuresis onset following aminophylline treatment 
precluded dialysis in the remaining seven patients (odds 
ratio 0.16; 95% CI: 0.04-0.71; P=0.03). Two out of eight 
patients among the controls died while three out of nine 
patients in the aminophylline arm died (hazard ratio 0.77; 
95% CI: 0.11-5.45; P=0.8). All patients were followed-
up for 7-42 days (median 19 days).
Discussion
Emerging data on aminophylline treatment of AKI 
showed that the agent could be useful in improving 
outcome as demonstrated by improved urine flow rates 
[9-11, 13-15], steady state Scr [11, 15] and reversal of 
nephrotoxic oliguria [10]. In this study, aminophylline 
was significantly associated with improved outcome 
with regards to UFR, oliguria/anuria duration, number of 
patients dialyzed, and Scr level. This occurred despite both 
groups having similar age, gender, etiology and severity 
of kidney injury. Both groups had similar baseline Scr, 
time to peak Scr and prevalence of oliguria/anuria and all 
patients progressed to stage 3 AKI. The increase in UFRs 
from baselines for days 5, 6, and 7, was significantly 
higher for the aminophylline arm compared to controls. 
This is similar to findings in two other controlled studies 
in children [10, 11]. This study also showed aminophylline 
to be protective against prolonged oliguria/anuria. The 
relatively steady Scr levels found in the aminophylline 
arm suggest increased creatinine excretion following 
improved urine flow rates. This effect probably explains 
why patients treated with aminophylline were less likely 
to be dialyzed compared to controls. However, these 
positive impacts of aminophylline on the hemodynamic 
Methods
This retrospective case control study was conducted by 
reviewing the clinical charts of all AKI patients treated 
with or without aminophylline during the period between 
January 2004 and December 2009. Investigated outcome 
indices comprised urine flow rate (UFR), duration 
of oliguria/anuria, progression through AKI stages, 
need for dialysis and mortality. Inclusion criteria were 
AKI diagnosed within 48 hours of onset. Patients were 
included in the aminophylline group if they started a 
72 hour aminophylline infusion within 72 hours of AKI 
onset. Exclusion criteria comprised non-oliguric AKI, 
insufficient serum creatinine (Scr) data, lack of daily 
urine volume records for at least one week, obstructive 
uropathy, bilateral congenital kidney anomaly or other 
forms of chronic kidney disease as well as administration 
of diuretics and/or calcium channel blockers. None 
of our patients received other drugs that can modify 
renal hemodynamics, such as dobutamine, dopamine 
and adrenaline. The clinical records revealed that the 
aminophylline arm received 5 mg/kg/24h (or 0.21 mg/
kg/h) of the medication for 72 hours, usually 6 to 9 hours 
after oliguria/anuria onset. Serum theophylline level 
was not determined. No adverse effect of aminophylline 
was recorded for any of the patients. Aminophylline 
was delivered in 10% dextrose water infusion. The 
AKI network (AKIN) committee diagnostic and staging 
criteria were used [4]. Where baseline Scr was unknown, 
it was determined using the modification of diet in renal 
disease formula {estimated glomerular filtration rate 
(eGFR) =186 x [Scr] – 1.154 x Age – 0.203 x 0.742 (if female) 
x 1.210 (if black)} [12] by assuming a normal pre-morbid 
eGFR value of 100 ml/min/1.73m2 in the patient as 
recommended by AKIN [4]. Pre-treatment and daily 
biochemical evaluations including Scr were performed 
in all patients. AKI was staged both at baseline and at 
the peak of kidney injury (highest recorded Scr before 
normalization or death) using the AKIN-Scr criterion. 
The baseline UFR was determined from at least a 6-hour 
urine output. UFR in the aminophylline and control arms 
for days 5, 6, and 7 were compared. Diuresis onset was 
regarded as early if UFR ≥ 0.5 ml/kg/h occurred within 
6 days and late if it occurred after 6 days of  AKI onset. 
The study was conducted at the Pediatric Nephrology and 
Hypertension Unit of the Obafemi Awolowo University 
Teaching Hospitals Complex, Osun State, Nigeria. 
The study conformed to the provisions of the revised 
Declaration of Helsinki, Edinburg, 2000. Our institutional 
ethics and research committee approved the study.
Data analyses were performed using the SPSS version 
15.0 for Windows (2006 SPSS Inc.). Descriptive 
statistics comprised median, mean, standard deviation, 
percentages, and proportions. The comparative statistics 
used were Chi-square test, Fisher’s exact test, Student’s 
t-test, Wilcoxon signed ranks test for comparison of the 
medians and odds or hazard ratio where appropriate. 
Kaplan-Meier survival analysis and the log rank test 
were used to compare survival. A P value < 0.05 was 
considered statistically significant.
Results
Sixteen AKI cases were treated with aminophylline 
overall. Seven of the 16 patients were excluded because 
they had received in addition to aminophylline either 
furosemide or a calcium channel blocker or both. 
Overall, 17 patients satisfied the inclusion criteria with 
nine and eight patients in the aminophylline and control 
arms, respectively. The mean ages for the control and 
aminophylline arms were 4.6 ± 2.7 (1.5-10.0) and 4.9 ±2.1 
(2.2-8.5) years, respectively (P=0.7). The aminophylline 
arm contained seven males and two females while the 
control arm contained four males and four females 
(P=0.2). Patients in the aminophylline arm received 
50-125 (81 ± 25) mg of aminophylline per day. Etiologies 
of AKI in both groups of patients are summarized in 
Table-1. All patients progressed to the most severe form 
of AKI (stage 3). Four patients were anuric and four 
Table 1: Etiology of acute kidney injury in the aminophylline and control arms
Acute kidney injury etiology Aminophylline arm (N=9)
Control 
arm (N=8)
P. falciparum malaria associated hemoglobinuria 5 3
Glucose 6-phosphate dehydrogenase enzyme deficiency associated hemoglobinuria 1 3
Septicemia 2 0
Gastroenteritis associated severe dehydration 0 1
Acute glomerulonephritis 0 1
Lupus nephritis 1 0
Figure 1: Box plots comparing the median increase in urine flow rates from baseline to days 5, 6 and 7 in the aminophylline 
and control arms
The lower and the upper arm of each box plot represent the 5th and 95th percentiles while the bottom and top of each box represents the 25th and 75th 
percentiles respectively.
38
Arab Journal of Nephrology and Transplantation
Olowu and Adefehinti Aminophylline therapy in acute kidney injury
events of the initiation and extension phases of AKI failed 
to translate to improved survival. Progression to stage 3 
AKI which could not be prevented by aminophylline was 
probably a factor. Stage 3 AKI is especially associated 
with dismal prognosis [1, 16, 17]. As in other studies, 
small sample size was an important limitation of this 
study. A large prospective randomized controlled study 
is therefore warranted to further evaluate the effect of 
aminophylline treatment on childhood AKI survival. 
Notwithstanding this limitation, the study has revealed 
that with improved UFR and reduced number of dialyzed 
patients, aminophylline treatment could potentially 
reduce the treatment cost of AKI.
Figure 2: Box plots comparing the median urine flow rates 
of the aminophylline and control arms
The lower and upper arm of each box plot represents the 5th and 95th 
percentile while the bottom and top of each box represents the 25th and 
75th percentile respectively.
Figure 3: Box plots comparing day 5 with days 6 and 7 median 
serum creatinine in aminophylline and control arms
The lower and upper arm of each box plot represents the 5th and 95th 
percentile while the bottom and top of each box represents the 25th and 
the 75th percentile respectively. 
Conclusion
Although there was no improvement in patients’ survival, 
the improved urine flow rates in the aminophylline 
treated group obviated the need for dialysis treatment in 
the majority of patients. This could impact positively on 
the overall AKI treatment cost.
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events of the initiation and extension phases of AKI failed 
to translate to improved survival. Progression to stage 3 
AKI which could not be prevented by aminophylline was 
probably a factor. Stage 3 AKI is especially associated 
with dismal prognosis [1, 16, 17]. As in other studies, 
small sample size was an important limitation of this 
study. A large prospective randomized controlled study 
is therefore warranted to further evaluate the effect of 
aminophylline treatment on childhood AKI survival. 
Notwithstanding this limitation, the study has revealed 
that with improved UFR and reduced number of dialyzed 
patients, aminophylline treatment could potentially 
reduce the treatment cost of AKI.
Figure 2: Box plots comparing the median urine flow rates 
of the aminophylline and control arms
The lower and upper arm of each box plot represents the 5th and 95th 
percentile while the bottom and top of each box represents the 25th and 
75th percentile respectively.
Figure 3: Box plots comparing day 5 with days 6 and 7 median 
serum creatinine in aminophylline and control arms
The lower and upper arm of each box plot represents the 5th and 95th 
percentile while the bottom and top of each box represents the 25th and 
the 75th percentile respectively. 
Conclusion
Although there was no improvement in patients’ survival, 
the improved urine flow rates in the aminophylline 
treated group obviated the need for dialysis treatment in 
the majority of patients. This could impact positively on 
the overall AKI treatment cost.
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